Astellas Pharma U.S., Inc.: September 2014

Astellas Pharma U.S., Inc.: September 2014

Founded: 
April 2005
Location: 
Northbrook, Ill.
Mission: 
To provide patients, customers, community and employees with a bright future by changing tomorrow.

Astellas Pharma U.S., Inc., is a U.S. affiliate of Tokyo-based Astellas Pharma Inc. Located in Northbrook, Illinois, the company serves as the headquarters for the Americas and employs nearly 3,000 people. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products.

Our commitment to changing tomorrow is measured not only by our focus on bringing innovative and effective new medicines to patients and physicians, but also by the importance we place on the impact we can make within the communities where we work and live. Astellas supports many causes and has created two initiatives to demonstrate our commitment: Changing Tomorrow Day, an annual, worldwide volunteer event, and Science WoRx, a nationwide mentoring program and online resource network for science teachers and their students.

Launched in April 2005, Astellas was formed through the historical merger of Japan's third and fifth largest pharmaceutical companies - Yamanouchi, founded in 1923, and Fujisawa, founded in 1894. Both companies possessed similarities where it matters most - philosophy and vision. But the companies also differed where it matters most - areas of therapeutic concentration and expertise.

Yamanouchi brought a record of developing blockbuster drugs, a pipeline full of promising new compounds and a sales and marketing culture of deeply grounded, data-driven expertise. Fujisawa brought dominance in transplantation, a soaring reputation for in-depth understanding of the disease states and treatments within its market niches, and a track record for developing high-profile, market - leading products that become new standards of care.

With an unrelenting commitment to R&D as a value-creating core of its business, Astellas is consolidated around complementary strengths from Yamanouchi and Fujisawa. Astellas stands on a much stronger, more advanced business platform than either of the former companies could have mounted individually.

At Astellas, we build on our proud specialty heritage to develop innovative products that improve the lives of patients. To achieve this goal, our strategy is to focus on select therapeutic areas in order to develop a deep understanding of specific health conditions and the unique needs of our patients and customers. Our U.S. product portfolio and rich clinical pipeline are grounded within these therapeutic areas.

We share the same values with Research!America to make research to improve health a higher national priority. For more information about Astellas Pharma U.S., Inc., please visit our website at www.astellas.us.

Jeffrey D. Bloss, M.D., is senior vice president of Astellas Scientific and Medical Affairs and oversees medical affairs in the Americas. The mission of Astellas Scientific and Medical Affairs is to "improve patients' lives through trusted scientific and medical expertise that bridges drug discovery, development and commercialization to establish the value of and ensure the safe and effective use of Astellas products."

Media Contacts

Suzanne Ffolkes
VP Communications
571-482-2710

Anna Briseño
Senior Manager of Communications
571-482-2737

Without continued support for health research, many of the most promising young scientists, their ideas and a myriad of potentially life-changing scientific breakthroughs will vanish into oblivion.
Paul Marinec, PhD; University of California San Francisco